Showing 11-20 of 1537 results for "".
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide, might one day …
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-based cohort using the National Health Insurance Service (NH…
- Regenerative Medicine in Action: Scarless Wound Recovery May Be Possible with New Autologous Blood Techniquehttps://practicaldermatology.com/news/regenerative-medicine-in-action-scarless-wound-recovery-may-be-possible-with-new-autologous-blood-technique/2461982/A new technology that utilizes autologous blood to produce three-dimensional microvascular implants may help make scarless wound recovery a reality. Led by Professor Joo H. Kang from the Department of Biomedical Engineering at UNIST, the team developed a microfluidic system capable of processing b…
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either systemic/biologic th…
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and acceptability of the anticip…
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in order to give dermatol…
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year. In advance…
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philog…
- FDA Nod for Cyltezo Autoinjector Penhttps://practicaldermatology.com/news/fda-nod-for-cyltezo-autoinjector-pen/2461738/The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). Cyltezo is an FDA-approved interchangeable biosimilar to Humira (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to …
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first time that scientists have direc…